Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Scientists map a giant parasite machine to fight tropical diseases

23

Sep 2026

Scientists map a giant parasite machine to fight tropical diseases

A study conducted between the University of Liège and Rockefeller University reveals, with near-atomic precision, the three-dimensional structure and function of a gigantic molecular machine essential to the survival of trypanosomatid parasites, which cause serious diseases in humans, animals and plants.

Feeling lonely at work? How often you see your colleagues may matter

23

Sep 2026

Feeling lonely at work? How often you see your colleagues may matter

In a nationally representative sample of 7,798 employees in Germany aged 25 to 65, about 26% reported lacking companionship from colleagues, 17% felt excluded, and 8% felt lonely at work at least sometimes. Less frequent direct contact with colleagues was consistently associated with all three facets of workplace loneliness, although the cross-sectional study cannot establish cause and effect.

Cancer-related DNA changes may appear in blood years before diagnosis

23

Sep 2026

Cancer-related DNA changes may appear in blood years before diagnosis

Researchers found that genome-wide plasma cfDNA methylation profiles collected before diagnosis contained early molecular signatures associated with future prostate and breast cancer, with prostate silencer methylation providing the stronger risk stratification. Breast enhancer signals were weaker and varied by subtype and disease stage, indicating that cfDNA methylation may have greater value for risk assessment and surveillance than as a standalone diagnostic test.

Could a parent’s hospital job shape a child’s nasal microbiome?

23

Sep 2026

Could a parent’s hospital job shape a child’s nasal microbiome?

A pilot study of 37 families found that children with healthcare-worker parents had lower nasal microbial diversity, with the largest differences among children whose two parents worked in healthcare. Porphyromonas was significantly less abundant, while Neisseria showed a similar non-significant pattern, but the cross-sectional study cannot establish causality or determine whether these microbiota differences affect health.

What links smoking, body fat, mental health, genes, and heart risk? Inflammation may be part of the answer

23

Sep 2026

What links smoking, body fat, mental health, genes, and heart risk? Inflammation may be part of the answer

In a large UK Biobank study, higher levels of the chronic inflammation marker GlycA were associated with smaller heart chambers, thicker heart walls, impaired diastolic function, reduced stroke volume, and a 43% higher risk of major adverse cardiovascular events in the highest versus lowest GlycA group. Genetic susceptibility also modified the associations between environmental exposures, inflammation, and cardiovascular risk, while inflammatory proteins in the IL-1, TNF, and IL-6 pathways statistically mediated several of these associations.

Why scientists still cannot say how much plastic infants are actually consuming

22

Sep 2026

Why scientists still cannot say how much plastic infants are actually consuming

A systematic review of 22 primary studies and four reviews found plastic-derived contaminants across infant foods and feeding equipment, but major differences in sampling, analytical methods, and quality control made exposure estimates difficult to compare. The authors found substantial evidence gaps for nanoplastics and oligomers and concluded that better-standardized exposure assessment is needed before infant health risks can be reliably evaluated.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.